Study to Evaluate SYN115 in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Parkinson's Disease
Interventions
DRUG

Placebo

"Placebo oral capsules~Placebo for 7 days"

DRUG

Tozadenant

20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID

Trial Locations (1)

63110

Washington University St. Louis, St Louis

Sponsors
All Listed Sponsors
lead

Biotie Therapies Inc.

INDUSTRY

NCT00605553 - Study to Evaluate SYN115 in Parkinson's Disease | Biotech Hunter | Biotech Hunter